{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:12:22Z","timestamp":1772165542559,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH\/NIAID","award":["R01 AI-176309"],"award-info":[{"award-number":["R01 AI-176309"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The accessible, easy to use and timely, diagnosis of tuberculosis (TB) drug-susceptibility, is often challenging, particularly in resource-constrained settings. We therefore evaluated the phenotypic thin-layer agar based MDR\/XDR-TB Colour Test, also known as the \u201cFirst Generation (1G) Color Plate Test (TB-CX)\u201d performance for detecting resistance of\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      (\n                      <jats:italic>Mtb<\/jats:italic>\n                      ) isolates to selected anti-TB drugs versus other tests routinely used in our setting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cross-sectional study was conducted on\n                      <jats:italic>Mtb<\/jats:italic>\n                      clinical isolates stored at the Armauer Hansen Research Institute TB laboratory in Addis Ababa, Ethiopia. Drug-susceptibility testing was performed on 78\n                      <jats:italic>Mtb<\/jats:italic>\n                      isolates for isoniazid, rifampicin, and moxifloxacin using the Colour Test and the Indirect Proportional Method (IPM) \u201cin house\u201d assay. Isoniazid and rifampicin were also evaluated by the Mycobacterial Growth Indicator Tube (MGIT) commercially available assay. Test accuracy was calculated as % agreement with 95% confidence intervals (95%CI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median (range) times in days determining\n                      <jats:italic>Mtb<\/jats:italic>\n                      resistance or susceptibility for the Colour Test, IPM and MGIT assays were of 9 (5\u201318), 15 (13\u201318) and 19 (14\u201321) days, respectively. The Colour Test provided results significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) more rapidly than the IPM or MGIT assays. The colour test showed a sensitivity and specificity of 91%(95% CI: 87\u201396) and 87%(95% CI:75\u201395) for detecting isoniazid resistance,and 93%(95% CI:81\u201399) and 92%(95% CI:82\u201397) for detecting rifampicin resistance, respectively, when compared to MGIT DST. For detecting MDR-TB the sensitivity and specificity were 90%(95% CI:76\u201397) and 96%(95% CI:88\u201399),respectively. The colour test showed a sensitivity of 97%(95%CI\u2009=\u200987\u2013100) and specificity of 89% (95%CI\u2009=\u200979\u201396) for detecting isoniazid resistance while for rifampicin resistance,it showed a sensitivity of 82%(95%CI\u2009=\u200964\u201393)and a specificity of 80%(95% CI\u2009=\u200968\u201390) rifampicin resistance. Colour Test accuracy compared to IPM to detect isoniazid, rifampicin resistance and MDR-TB was 92% (95%CI\u2009=\u200986\u201398), 81% (95%CI\u2009=\u200972\u201390), and 90% (95%CI\u2009=\u200983\u201396). IPM test accuracy compared to MGIT DST for detecting isoniazid and rifampicin resistance and MDR-TB was 91% (95%CI\u2009=\u200985\u201397), 83% (95%CI\u2009=\u200975\u201392), and 85% (95%CI\u2009=\u200977\u201393), respectively. Moxifloxacin drug-susceptibility testing could not be assessed because only two isolates showed evidence of resistance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The accuracy of\n                      <jats:italic>Mtb<\/jats:italic>\n                      drug-susceptibility testing was similar comparing: Colour Test versus IPM, Colour Test versus MGIT; and comparing IPM versus MGIT. The Colour Test was easy to use and determined drug-susceptibility significantly more rapidly than the IPM and MGIT assays. Thus, implementing the Colour Test in clinical settings could make drug-susceptibility testing more accessible and rapid in high TB burden, and resource-constrained settings, including in Ethiopia.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12866-025-04347-z","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:18:30Z","timestamp":1760062710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Performance of the low-cost phenotypic thin-layer agar MDR\/XDR-TB Colour Test (first generation, 1G, Color Plate Test) for identifying drug-resistant Mycobacterium tuberculosis isolates in a resource-limited setting"],"prefix":"10.1186","volume":"25","author":[{"given":"Binyam","family":"Mebrat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan I.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimtubezenash","family":"Woldeamanuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelemework","family":"Adane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amberlee","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melaku","family":"Tilahun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebsib","family":"Neway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lelisa","family":"Oluma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abay","family":"Atnafu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Gelfond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlton A.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi B.","family":"Torrelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liya","family":"Wassie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"issue":"4","key":"4347_CR1","first-page":"1236","volume":"47","author":"D Van Soolingen","year":"1997","unstructured":"Van Soolingen D, Hoogenboezem T, De Haas PE, Hermans PW, Koedam MA, Teppema KS, et al. A novel pathogenic taxon of the Mycobacterium tuberculosis complex, Canetti: characterization of an exceptional isolate from Africa. Int J Syst Evol Microbiol. 1997;47(4):1236\u201345.","journal-title":"Int J Syst Evol Microbiol"},{"key":"4347_CR2","volume-title":"Geneva","author":"WH Organization","year":"2024","unstructured":"Organization WH. Geneva. Global Tuberculosis Report: Switzerland; 2024."},{"key":"4347_CR3","doi-asserted-by":"publisher","first-page":"1207284","DOI":"10.3389\/fpubh.2023.1207284","volume":"11","author":"Y-J Jeong","year":"2023","unstructured":"Jeong Y-J, Park JS, Kim HW, Min J, Ko Y, Oh JY, et al. Deaths from tuberculosis: differences between tuberculosis-related and non-tuberculosis-related deaths. Front Public Health. 2023;11:1207284.","journal-title":"Front Public Health"},{"issue":"1","key":"4347_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00504-2","volume":"10","author":"K Dheda","year":"2024","unstructured":"Dheda K, Mirzayev F, Cirillo DM, Udwadia Z, Dooley KE, Chang K-C, et al. Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024;10(1):22.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"4347_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001271","volume":"3","author":"N Arinaminpathy","year":"2023","unstructured":"Arinaminpathy N, Mukadi YD, Bloom A, Vincent C, Ahmedov S. Meeting the 2030 END TB goals in the wake of COVID-19: a modelling study of countries in the USAID TB portfolio. PLoS Glob Public Health. 2023;3(10):e0001271.","journal-title":"PLoS Glob Public Health"},{"issue":"1","key":"4347_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/jac\/dkn139","volume":"62","author":"A Martin","year":"2008","unstructured":"Martin A, Panaiotov S, Portaels F, Hoffner S, Palomino JC, Angeby K. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother. 2008;62(1):56\u201364.","journal-title":"J Antimicrob Chemother"},{"issue":"15","key":"4347_CR7","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMoa055524","volume":"355","author":"DA Moore","year":"2006","unstructured":"Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, Vivar A, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med. 2006;355(15):1539\u201350.","journal-title":"N Engl J Med"},{"key":"4347_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijid.2019.10.041","volume":"90","author":"A Shibabaw","year":"2020","unstructured":"Shibabaw A, Gelaw B, Kelley HV, Tesfaye E, Balada-Llasat JM, Evans CA, et al. MDR\/XDR-TB colour test for drug susceptibility testing of Mycobacterium tuberculosis, Northwest Ethiopia. Int J Infect Dis. 2020;90:213\u20138.","journal-title":"Int J Infect Dis"},{"key":"4347_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.870768","volume":"13","author":"KA Yusoof","year":"2022","unstructured":"Yusoof KA, Garcia JI, Schami A, Garcia-Vilanova A, Kelley HV, Wang S-H, et al. Tuberculosis phenotypic and genotypic drug susceptibility testing and immunodiagnostics: a review. Front Immunol. 2022;13:870768.","journal-title":"Front Immunol"},{"issue":"suppl_2","key":"4347_CR10","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1093\/infdis\/jis194","volume":"205","author":"P Nahid","year":"2012","unstructured":"Nahid P, Kim PS, Evans CA, Alland D, Barer M, Diefenbach J, et al. Clinical research and development of tuberculosis diagnostics: moving from silos to synergy. J Infect Dis. 2012;205(suppl_2):S159\u201368.","journal-title":"J Infect Dis"},{"key":"4347_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.tube.2018.11.007","volume":"114","author":"A Shibabaw","year":"2019","unstructured":"Shibabaw A, Gelaw B, Kelley H, Balada-Llasat JM, Evans C, Wang S-H, et al. Accuracy of the color plate micro-colony detection for the diagnosis of Mycobacterium tuberculosis complex in Northwest Ethiopia. Tuberculosis. 2019;114:54\u201360.","journal-title":"Tuberculosis"},{"issue":"8","key":"4347_CR12","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.5588\/ijtld.11.0609","volume":"16","author":"K Toit","year":"2012","unstructured":"Toit K, Mitchell S, Balabanova Y, Evans C, Kummik T, Nikolayevskyy V, et al. The colour test for drug susceptibility testing of Mycobacterium tuberculosis strains. Int J Tuberc Lung Dis. 2012;16(8):1113\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4347_CR13","unstructured":"World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. Geneva: World Health Organization; 2018. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241514842"},{"key":"4347_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijid.2020.12.071","volume":"104","author":"K Klaos","year":"2021","unstructured":"Klaos K, Agejeva A, Kummik T, Laks S, Remets O, Sasi S, et al. A successful introduction to a non-expert setting of the thin-layer agar colour test as an indirect phenotypic drug susceptibility test for Mycobacterium tuberculosis. Int J Infect Dis. 2021;104:19\u201326.","journal-title":"Int J Infect Dis"},{"key":"4347_CR15","doi-asserted-by":"crossref","unstructured":"Mekonnen B, Mihret A, Getahun M, Hailu T, Sidiki S, Kelley HV, et al. Evaluation of the tuberculosis culture color plate test for rapid detection of drug-susceptible and drug-resistant Mycobacterium tuberculosis in a resource-limited setting, Addis Ababa, Ethiopia. PLoS One. 2019;14(5):e0215679. doi:10.1371\/journal.pone.0215679.","DOI":"10.1371\/journal.pone.0215679"},{"issue":"1","key":"4347_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/1756-0500-7-512","volume":"7","author":"W Wedajo","year":"2014","unstructured":"Wedajo W, Sch\u00f6n T, Bedru A, Kiros T, Hailu E, Mebrahtu T, et al. A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting. BMC Res Notes. 2014;7(1):512.","journal-title":"BMC Res Notes"},{"key":"4347_CR17","unstructured":"\u0160imundi\u0107 A-M. Measures of diagnostic accuracy: basic definitions. EJIFCC. 2009;19(4):203\u201311. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4975285\/."},{"issue":"1","key":"4347_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.mimet.2009.05.001","volume":"78","author":"A Martin","year":"2009","unstructured":"Martin A, Fissette K, Varaine F, Portaels F, Palomino JC. Thin layer agar compared to BACTEC MGIT 960 for early detection of Mycobacterium tuberculosis. J Microbiol Methods. 2009;78(1):107\u20138.","journal-title":"J Microbiol Methods"},{"key":"4347_CR19","doi-asserted-by":"crossref","unstructured":"Agumas Shibabaw AS, Baye Gelaw BG, Kelley H, Ephrem Tesfaye ET, Balada-Llasat J, Evans C, et al. MDR\/XDR-TB Colour Test for drug susceptibility testing of Mycobacterium tuberculosis, Northwest Ethiopia. International Journal of Infectious Diseases. 2020 Jan 1; 90:213-8.","DOI":"10.1016\/j.ijid.2019.10.041"},{"key":"4347_CR20","unstructured":"Dickinson. B. BD BACTEC\u2122 MGIT\u2122 960 SIRE Kits For the Antimycobacterial Susceptibility Testing of Mycobacterium tuberculosis. 2019 [Available from: https:\/\/www.bd.com\/resource.aspx?IDX=18269."},{"key":"4347_CR21","unstructured":"Ajbani K, Comas I, Coulter C, Kelly E, Fournier Le Ray L, Kambli P, et al. Technical Report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine).Geneva;World Health Organization; 2021. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/339275\/9789240017283-eng.pdf."},{"issue":"12","key":"4347_CR22","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.5588\/ijtld.15.0136","volume":"19","author":"E Ardizzoni","year":"2015","unstructured":"Ardizzoni E, Mulders W, Kotrikadze T, Aspindzelashvili R, Goginashvili L, Pangtey H, et al. The thin-layer agar method for direct phenotypic detection of multi-and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19(12):1547\u201352.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"4347_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/0923-2508(89)90016-8","volume":"140","author":"N Rastogi","year":"1989","unstructured":"Rastogi N, Goh K, David H. Drug susceptibility testing in tuberculosis: a comparison of the proportion methods using Lowenstein-Jensen, Middlebrook 7H10 and 7H11 agar media and a radiometric method. Res Microbiol. 1989;140(5):405\u201317.","journal-title":"Res Microbiol"},{"issue":"2","key":"4347_CR24","first-page":"295","volume":"98","author":"ML Cohn","year":"1968","unstructured":"Cohn ML, Waggoner RF, McClatchy JK. The 7Hll medium for the cultivation of mycobacteria. Am Rev Respir Dis. 1968;98(2):295\u20136.","journal-title":"Am Rev Respir Dis"},{"issue":"3","key":"4347_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/labmed\/9.3.47","volume":"9","author":"MJ Kenneth","year":"1978","unstructured":"Kenneth MJ. Susceptibility testing of mycobacteria. Laboratory Medicine. 1978;9(3):47\u201352.","journal-title":"Laboratory Medicine"},{"key":"4347_CR26","unstructured":"World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization; 2024. Available from: https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024."},{"key":"4347_CR27","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0226-2022","author":"A Vasiliu","year":"2023","unstructured":"Vasiliu A, Saktiawati AMI, Duarte R, Lange C, Cirillo DM. Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries. Breathe. 2023. https:\/\/doi.org\/10.1183\/20734735.0226-2022.","journal-title":"Breathe"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04347-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-025-04347-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04347-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:18:38Z","timestamp":1760062718000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-025-04347-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4347"],"URL":"https:\/\/doi.org\/10.1186\/s12866-025-04347-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6697928\/v1","asserted-by":"object"}]},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Research Ethics Committee of the Department of Microbiology, Immunology and Parasitology, College of Health Sciences, Addis Ababa University, and the AHRI\/All Africa Leprosy and Tuberculosis Rehabilitation and Training Center (ALERT) Ethics Review Committee (Protocol number PO-07\/23). Waiver of consent to use stored isolates was obtained from the AHRI\/All Africa Leprosy and Tuberculosis Rehabilitation and Training Center (ALERT) Ethics Review Committee (Protocol number PO-07\/23). Our study adhered to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"652"}}